For over 30 years, quests for rare genetic variants causing disease were rewarded for having good positional sense (linkage analysis) and educated guesswork (candidate gene analysis). Recently, novel 'NextGen'DNA sequencing methods have found rare variants by sequencing all known exons (the 'exome'). This application of a genomics solution to a traditionally genetics problem has fundamentally redefined how to solve the 'rare variant'question. The paradigm shift may soon render traditional PCR based analyses obsolete and is reminiscent of how GWAS studies (e.g. NIH GWAS Initiative) are solving the common variant problem. However, currently exome sequencing has mainly explored rare diseases, false positives remain an issue, and validation of findings in large follow-up cohorts has not been done. Our group has been studying a decidedly morbid condition and 'non-rare'condition, hereditary dilated cardiomyopathy (DCM) (prevalence ~1:500), which represents the first and third leading causes of heart transplant and heart failure, respectively. Over 600 families with extensive clinical data and DNA have been collected by our international registry. A key existing knowledge gap is that two-thirds of the genetic causes of DCM are still unknown. Traditional approaches (linkage/candidate analyses) have largely stalled, confounded in part by high genetic heterogeneity and the difficulties of locating large enough families for study. Novel approaches are needed to address bridge this knowledge gap, improve our understanding of disease etiology, and direct us to new targets for DCM treatment. To solve this knowledge gap, we propose to use NextGen whole genome sequencing large, multigenerational families. Our hypothesis is that our two-step genomics solution of 'gene discovery'followed by 'gene validation'will reveal novel DCM genes.
In Aim 1, 20 large families will undergo genome sequencing for gene discovery (Illumina HiSeq2000). Three innovative bioinformatic steps (filtering by segregation / by gene/pathway analysis / a novel bioinformatic analysis that prioritizes exome variants) will markedly reducing false-positive findings.
In Aim 2, novel genes (Aim 1) will be sequenced in a validation cohort of 200 DCM families. Innovative components of our project are: genome sequencing in a 'non-rare'and highly morbid disease, use of segregation analysis in extended pedigrees, our novel bioinformatic strategy we call E1P2I3, and validation in a replication cohort. The impact of this work will include discovery of novel DCM genes, development of new DCM genetic tests, improvement in understanding of DCM etiology, and illumination of potential new therapeutic strategies.
Idiopathic dilated cardiomyopathy represents the first and third leading causes of cardiac transplantation and hearth failure, respectively. Although many cases are strongly suspected to be genetic, currently two-thirds of cases have no identifiable disease gene, strongly arguing for the development of novel approaches to finding new genes for this disease. We propose to use cutting-edge DNA sequencing to discover new DCM genes using a novel two phase design of 'gene discovery'followed by 'gene validation'to solve this knowledge gap. Our data will shed much needed light on disease etiology, advance diagnostics, and pave the way for developing novel therapies.
|Sweet, Mary E; Mestroni, Luisa; Taylor, Matthew R G (2018) Genetic Infiltrative Cardiomyopathies. Heart Fail Clin 14:215-224|
|Sweet, Mary E; Cocciolo, Andrea; Slavov, Dobromir et al. (2018) Transcriptome analysis of human heart failure reveals dysregulated cell adhesion in dilated cardiomyopathy and activated immune pathways in ischemic heart failure. BMC Genomics 19:812|
|Laurini, Erik; Martinelli, Valentina; Lanzicher, Thomas et al. (2018) Biomechanical defects and rescue of cardiomyocytes expressing pathologic nuclear lamins. Cardiovasc Res 114:846-857|
|Begay, Rene L; Graw, Sharon L; Sinagra, Gianfranco et al. (2018) Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell-Cell Adhesion Structures. JACC Clin Electrophysiol 4:504-514|
|Te Riele, Anneline S J M; Agullo-Pascual, Esperanza; James, Cynthia A et al. (2017) Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovasc Res 113:102-111|
|Peña, Brisa; Bosi, Susanna; Aguado, Brian A et al. (2017) Injectable Carbon Nanotube-Functionalized Reverse Thermal Gel Promotes Cardiomyocytes Survival and Maturation. ACS Appl Mater Interfaces 9:31645-31656|
|D'souza, Ryan S; Mestroni, Luisa; Taylor, Matthew R G (2017) Danon disease for the cardiologist: case report and review of the literature. J Community Hosp Intern Med Perspect 7:107-114|
|Chen, Suet Nee; Taylor, Matthew; Mestroni, Luisa (2017) Unraveling Missing Genes and Missing Inheritance in Arrhythmogenic Cardiomyopathy. Circ Arrhythm Electrophysiol 10:|
|Tatman, Philip D; Woulfe, Kathleen C; Karimpour-Fard, Anis et al. (2017) Pediatric dilated cardiomyopathy hearts display a unique gene expression profile. JCI Insight 2:|
|Rowland, Teisha J; Sweet, Mary E; Mestroni, Luisa et al. (2016) Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy. J Cell Sci 129:2135-43|
Showing the most recent 10 out of 29 publications